Dr. David A. Wohl, M.D.
Infectious Disease (Infectious Disease Physician)
- Medicare participating
At a glance
- Medical school
- Rowan University School of Osteopathic Medicine (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 53
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: Rowan University School of Osteopathic Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
NC license 9400396
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Unc Hospitals Chapel Hill, NC
Medical groups
- University of North Carolina at Chapel Hill (2,052 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 53
- Services billed
- 187
- Patients’ average age
- 67
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 55 | 14 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 51 | 14 |
| Established patient office or other outpatient visit, 40-54 minutes | 17 | 13 |
| Established patient office or other outpatient visit, 30-39 minutes | 16 | 14 |
| Insertion of needle into vein for collection of blood sample | 16 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Biktarvy (bictegrav/emtricit/tenofov ala) | 253 |
| Tivicay (dolutegravir sodium) | 183 |
| Descovy (emtricitabine/tenofov alafenam) | 171 |
| Atorvastatin Calcium Other prescribers in Chapel Hill, NC | 119 |
| Amlodipine Besylate Other prescribers in Chapel Hill, NC | 67 |
| Gabapentin Other prescribers in Chapel Hill, NC | 61 |
| Oxycodone Hcl Other prescribers in Chapel Hill, NC | 49 |
| Methadone Hcl Other prescribers in Chapel Hill, NC | 46 |
| Enalapril Maleate Other prescribers in Chapel Hill, NC | 45 |
| Dovato (dolutegravir sodium/lamivudine) | 42 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 78 payments worth $76,334 in total to this clinician.
| Merck Sharp & Dohme LLC | $25,240 |
|---|---|
| Gilead Sciences, Inc. | $23,765 |
| Viiv Healthcare Company | $19,145 |
| Theratechnologies Inc. | $5,002 |
| Shionogi Inc | $3,182 |
| Consulting Fee | $59,510 |
|---|---|
| Travel and Lodging | $7,509 |
| Honoraria | $3,960 |
| Compensation for services other than consulting (speaking, faculty) | $3,182 |
| Food and Beverage | $2,173 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Oct 15, 2025 | Consulting Fee | $10,440 |
| Gilead Sciences, Inc. Apr 16, 2025 | Consulting FeeCompany’s description;3978884;GTF;10018958 | $8,920 |
| Viiv Healthcare Company Apr 2, 2025 | Consulting Fee | $6,500 |
| Viiv Healthcare Company Apr 2, 2025 | Consulting Fee | $6,500 |
| Gilead Sciences, Inc. Dec 8, 2025 | Consulting Fee Sunlenca · HIV Company’s description;4288216;GTF;10018958 | $5,950 |
| Merck Sharp & Dohme LLC Feb 24, 2025 | Consulting Fee | $5,220 |
| Merck Sharp & Dohme LLC Nov 24, 2025 | Consulting Fee | $4,640 |
| Theratechnologies Inc. Dec 15, 2025 | Honoraria EGRIFTA · HIV | $3,960 |
| Viiv Healthcare Company Aug 5, 2025 | Consulting Fee | $3,900 |
| Shionogi Inc Feb 17, 2025 | Compensation for services other than consulting (speaking, faculty) S-217622 · Infections and Infectious Diseases | $3,182 |
All 43 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Theratechnologies Inc. Dec 15, 2025 | Honoraria EGRIFTA · HIV | $3,960 |
| Theratechnologies Inc. Dec 15, 2025 | Travel and Lodging EGRIFTA · HIV · travel to Dallas, TX | $64.00 |
| Gilead Sciences, Inc. Dec 8, 2025 | Consulting Fee Sunlenca · HIV Company’s description;4288216;GTF;10018958 | $5,950 |
| Merck Sharp & Dohme LLC Nov 24, 2025 | Consulting Fee | $4,640 |
| Merck Sharp & Dohme LLC Nov 24, 2025 | Travel and Lodging travel to Philadelphia, PA | $150 |
| Merck Sharp & Dohme LLC Nov 18, 2025 | Travel and Lodging PIFELTRO · INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $411 |
| Merck Sharp & Dohme LLC Nov 17, 2025 | Travel and Lodging PIFELTRO · INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $709 |
| Merck Sharp & Dohme LLC Nov 17, 2025 | Travel and Lodging PIFELTRO · INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $313 |
| Gilead Sciences, Inc. Nov 14, 2025 | Travel and Lodging Sunlenca · HIV · travel to Boston, MA · in-kind Company’s description;4288250;GTF;10018958 | $313 |
| Gilead Sciences, Inc. Nov 14, 2025 | Travel and Lodging Sunlenca · HIV · travel to Boston, MA · in-kind Company’s description;4288109;GTF;10018958 | $58.30 |
| Gilead Sciences, Inc. Nov 13, 2025 | Travel and Lodging Sunlenca · HIV · travel to Boston, MA · in-kind Company’s description;4288185;GTF;10018958 | $367 |
| Gilead Sciences, Inc. Nov 13, 2025 | Travel and Lodging Sunlenca · HIV · travel to Boston, MA · in-kind Company’s description;4288254;GTF;10018958 | $160 |
| Gilead Sciences, Inc. Nov 13, 2025 | Travel and Lodging Sunlenca · HIV · travel to Boston, MA Company’s description;4288189;GTF;10018958 | $64.00 |
| Theratechnologies Inc. Nov 6, 2025 | Travel and Lodging EGRIFTA · HIV · travel to Dallas, TX · in-kind | $239 |
| Viiv Healthcare Company Nov 3, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $250 |
| Theratechnologies Inc. Oct 20, 2025 | Travel and Lodging EGRIFTA · HIV · travel to Dallas, TX · in-kind | $534 |
| Merck Sharp & Dohme LLC Oct 15, 2025 | Consulting Fee | $10,440 |
| Gilead Sciences, Inc. Oct 15, 2025 | Consulting Fee Biktarvy · HIV Company’s description;4285347;VEM US;10018958 | $2,850 |
| Merck Sharp & Dohme LLC Oct 15, 2025 | Travel and Lodging travel to Philadelphia, PA | $150 |
| Viiv Healthcare Company Oct 9, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $248 |
| Viiv Healthcare Company Oct 9, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $31.41 |
| Merck Sharp & Dohme LLC Sep 29, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $260 |
| Merck Sharp & Dohme LLC Sep 28, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $681 |
| Merck Sharp & Dohme LLC Sep 28, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $275 |
| Merck Sharp & Dohme LLC Sep 28, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $260 |
| Merck Sharp & Dohme LLC Sep 28, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $171 |
| Viiv Healthcare Company Aug 5, 2025 | Consulting Fee | $3,900 |
| Gilead Sciences, Inc. Apr 16, 2025 | Consulting FeeCompany’s description;3978884;GTF;10018958 | $8,920 |
| Viiv Healthcare Company Apr 2, 2025 | Consulting Fee | $6,500 |
| Viiv Healthcare Company Apr 2, 2025 | Consulting Fee | $6,500 |
| Viiv Healthcare Company Apr 2, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $205 |
| Gilead Sciences, Inc. Mar 31, 2025 | Consulting FeeCompany’s description;4147546;VEM US;10018958 | $1,740 |
| Viiv Healthcare Company Mar 12, 2025 | Travel and Lodging travel to San Francisco, CA · in-kind | $287 |
| Gilead Sciences, Inc. Mar 6, 2025 | Consulting FeeCompany’s description;4146837;VEM US;10018958 | $2,850 |
| Viiv Healthcare Company Feb 28, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $441 |
| Viiv Healthcare Company Feb 28, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $31.02 |
| Merck Sharp & Dohme LLC Feb 24, 2025 | Consulting Fee | $5,220 |
| Merck Sharp & Dohme LLC Feb 24, 2025 | Travel and Lodging travel to Newark, NJ | $150 |
| Shionogi Inc Feb 17, 2025 | Compensation for services other than consulting (speaking, faculty) S-217622 · Infections and Infectious Diseases | $3,182 |
| Merck Sharp & Dohme LLC Feb 11, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Elizabeth, NJ · in-kind | $144 |
| Merck Sharp & Dohme LLC Feb 11, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Elizabeth, NJ · in-kind | $120 |
| Merck Sharp & Dohme LLC Feb 10, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Elizabeth, NJ · in-kind | $213 |
| Merck Sharp & Dohme LLC Feb 10, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Elizabeth, NJ · in-kind | $207 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $3,780 in research payments for these studies, mostly to the institutions running them.
- STUDY NAME#Demonstration of the feasibility of supported HCV treatment and eradication among persons with serious substance abuse disorders
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.